United States - English - NLM (National Library of Medicine)

virbac ah, inc. - tulathromycin (unii: q839i13422) (tulathromycin - unii:q839i13422) - swine tulissin 25 injectable solution is indicated for the treatment of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, bordetella bronchiseptica, haemophilus parasuis, and mycoplasma hyopneumoniae ; and for the control of srd associated with actinobacillus pleuropneumoniae, pasteurella multocida, and mycoplasma hyopneumoniae in groups of pigs where srd has been diagnosed. suckling calves, dairy calves, and veal calves brd - tulissin 25 injectable solution is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni, and mycoplasma bovis. the use of tulissin 25 injectable solution is contraindicated in animals previously found to be hypersensitive to the drug. residue warnings swine swine intended for human consumption must not be slaughtered within 5 days from the last treatment. calves calves intended for human consumption must not be slaughtered within 22

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.); pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u; pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u - modified release capsule - 300 mg - active: pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع السلام - salam drug store - cholecalciferol 25,000 iu/1ml - 25,000 iu/1ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة سنا فارما - sana pharma company - benzyl benzoate 25 gram/100 gram - 25 gram/100 gram